What is the appropriate management for a 195‑lb physician resident with chronic sleep maintenance insomnia, mild supine‑dependent obstructive sleep apnea (overall apnea‑hypopnea index ~9, REM apnea‑hypopnea index 5), allergic rhinitis treated with montelukast and loratadine‑D, recent weight gain, and no significant daytime sleepiness?

Initiate Cognitive Behavioral Therapy for Insomnia (CBT-I) as First-Line Treatment and Address Mild OSA Through Weight Loss and Positional Therapy

You should start with CBT-I for the chronic insomnia while simultaneously implementing weight loss and positional therapy for the mild supine-dependent obstructive sleep apnea. 1

Primary Management Strategy

1. Cognitive Behavioral Therapy for Insomnia (CBT-I)

The American College of Physicians provides a strong recommendation that CBT-I be the initial treatment for chronic insomnia disorder 1. This patient's presentation—frequent nighttime awakenings, nonrestorative sleep, early morning awakening with inability to return to sleep—represents classic sleep maintenance insomnia that responds well to CBT-I.

Key CBT-I components to implement:

• Sleep restriction therapy: Limit time in bed to actual sleep time (currently ~5 hours based on TST of 297 minutes), then gradually increase as sleep efficiency improves
• Stimulus control: Strengthen bed-sleep association, establish consistent sleep-wake times
• Cognitive therapy: Address maladaptive beliefs about sleep (e.g., the concern about "not actually sleeping" when attempting to return to sleep)
• Sleep hygiene optimization: Already partially implemented (sleep mask, earplugs, caffeine cutoff at 4 PM)

CBT-I can be delivered via multiple modalities including in-person, telephone, web-based modules, or self-help books 1. Given this patient is a physician resident, digital CBT-I platforms may be particularly accessible.

2. Address the Mild OSA Through Non-PAP Interventions

The polysomnography reveals mild OSA (AHI 9) that is supine-dependent and REM-related (AHI in supine only, REM AHI 5, non-REM AHI 1). Critically, the patient slept only in the supine position during the study, which artificially elevates the overall AHI.

Specific interventions:

Weight Loss (Primary Intervention):

• Target 10-15 kg weight reduction through comprehensive lifestyle intervention combining reduced-calorie diet with behavioral modification 2
• Evidence shows that very low calorie diet (VLCD) with supervised lifestyle counseling effectively treats mild OSA, with strong associations between weight/waist circumference changes and AHI reduction 2
• A 10.7 kg weight loss achieved sustained improvement in mild OSA at 1-year follow-up 2
• The patient has already identified recent weight gain and decreased activity—capitalize on this awareness

Positional Therapy:

• Implement supine sleep avoidance techniques (tennis ball shirt, positional alarms, or commercial positional devices)
• Since the patient only slept supine during the study and has non-REM AHI of 1, avoiding supine position could potentially normalize the AHI entirely

3. Optimize Allergic Rhinitis Management

The patient takes montelukast and loratadine-D at night for cat allergies. Allergic rhinitis increases OSA risk through increased nasal resistance and pharyngeal narrowing 3.

Consider:

• Adding intranasal corticosteroids (e.g., fluticasone, mometasone)—these have been shown to improve OSA when treating concomitant allergic rhinitis 3
• The current montelukast may provide some benefit for OSA in the context of allergic rhinitis, though data are limited 3
• Ensure environmental control measures (HEPA filters, allergen avoidance)

Why NOT CPAP at This Time

CPAP is not indicated for this patient's mild OSA for several reasons:

1. Lack of significant daytime sleepiness: The patient denies dozing during sedentary activities and has no documented excessive daytime sleepiness (ESS not completed, but clinical history suggests minimal impairment)
2. Minimal hypoxemia: Lowest SaO2 was 90%, average 95%—no significant oxygen desaturation
3. Evidence shows limited benefit in mild OSA without sleepiness: A randomized controlled trial of CPAP in mild OSA (AHI 5-30, mean 12.9) showed no improvement in objective sleepiness, neurobehavioral function, quality of life, mood, or blood pressure compared to placebo 4
4. The insomnia is the dominant clinical problem: Research specifically examining patients with insomnia and mild OSA found that treating underlying OSA first was more successful than CBT-I alone 5, but this was in the context of surgical intervention. For mild, positional OSA, conservative measures are more appropriate
5. CPAP may worsen insomnia: Introducing CPAP could exacerbate sleep maintenance difficulties in someone already struggling with frequent awakenings

Pharmacotherapy Considerations (If CBT-I Insufficient)

Only consider pharmacotherapy if CBT-I alone is unsuccessful after adequate trial (typically 4-8 weeks) 1, 6. The ACP provides a weak recommendation for shared decision-making regarding short-term medication use 1.

If needed, evidence-based options include:

• Low-dose doxepin (3-6 mg): Improves sleep maintenance, FDA-approved for insomnia 1, 7
• Lemborexant or other dual orexin receptor antagonists: Recent evidence shows lemborexant reduces insomnia severity in patients with comorbid insomnia and mild OSA without impairing next-morning cognition or alertness 8
• Avoid: Benzodiazepines and traditional "Z-drugs" (zolpidem, eszopiclone) given concerns about respiratory depression in OSA, though the OSA here is very mild

Note on melatonin: The patient previously tried melatonin with benefit but discontinued due to next-day "bodily heaviness." This suggests he may be sensitive to sedating effects. If reconsidering, use lower doses (0.5-1 mg) or time-release formulations.

Clinical Monitoring and Reassessment

Follow-up schedule:

• 2-4 weeks: Assess CBT-I implementation, weight loss progress, positional therapy adherence
• 8-12 weeks: Reassess insomnia symptoms (use Insomnia Severity Index), evaluate weight change, consider repeat sleep study if weight loss ≥5 kg or symptoms persist
• Every 6 months: Long-term monitoring given high relapse rate for insomnia 6

Repeat polysomnography indications:

• After ≥10% weight loss to document OSA improvement
• If insomnia persists despite adequate CBT-I trial and weight loss
• If new symptoms develop (witnessed apneas, severe daytime sleepiness)

Critical Pitfalls to Avoid

1. Don't jump to CPAP: The mild, positional OSA with minimal symptoms does not warrant CPAP as first-line therapy
2. Don't prescribe hypnotics without CBT-I trial: Medications should supplement, not replace, behavioral therapy 1, 6
3. Don't ignore the weight gain: This is likely the primary driver of the OSA and potentially contributing to insomnia through sleep fragmentation
4. Don't overlook the allergic rhinitis: Undertreated nasal inflammation may be perpetuating both conditions
5. Don't dismiss the "limited REM sleep" concern: While consumer sleep trackers (Oura Ring) are not diagnostic, the PSG confirms prolonged REM latency (366 minutes)—this may improve with insomnia treatment and OSA resolution

The Integrated Approach

This patient has COMISA (comorbid insomnia and OSA), but the OSA is mild and highly amenable to conservative management. The evidence strongly supports addressing both conditions simultaneously through non-pharmacologic means first 5, 9. The combination of CBT-I, weight loss, and positional therapy addresses the underlying pathophysiology of both disorders while avoiding the risks and adherence challenges of CPAP in someone with minimal OSA-related symptoms.